Zhitong Finance App News, Shanghai Laishi (002252.SZ) issued an announcement. The company's product “SR604 Injection” recently publicized the “Prevention and Treatment of Hemorrhagic Attacks in Hemophilia A/B Patients” phase III clinical trial registration information on the drug clinical trial registration and information disclosure platform of the State Drug Administration. Test name: Evaluating the efficacy and safety of SR604 injection in hemophilia A/B patients with or without inhibitors. The purpose of the single-arm, multi-center phase III clinical trial is to evaluate the efficacy and safety of SR604 injections in hemophilia A/B patients with or without inhibitors. The effectiveness of preventive treatment in /B patients.

Zhitong Finance App News, Shanghai Laishi (002252.SZ) issued an announcement. The company's product “SR604 Injection” recently publicized the “Prevention and Treatment of Hemorrhagic Attacks in Hemophilia A/B Patients” phase III clinical trial registration information on the drug clinical trial registration and information disclosure platform of the State Drug Administration. Test name: Evaluating the efficacy and safety of SR604 injection in hemophilia A/B patients with or without inhibitors. The purpose of the single-arm, multi-center phase III clinical trial is to evaluate the efficacy and safety of SR604 injections in hemophilia A/B patients with or without inhibitors. The effectiveness of preventive treatment in /B patients.